Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jichi Medical University
With
Boehringer Ingelheim
Eli Lilly and Company
The study consists of a 8-week run-in period and a 12-week treatment period.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who meet the following criteria at the start of treatment are eligible for the study:
Receiving stable treatment with anti-hypertensive including ARB for at least 8 weeks at baseline (0W).
Receiving stable anti-diabetic treatment with/without anti-diabetics for at least 8 weeks at baseline (0W).
HbA1c\>=6.0%, \<10%
Seated office SBP 130-159mmHg or DBP 80-99mmHg
Nocturnal hypertension (SBP\>=115 mmHg) as measured by Home BP during 5days before baseline (0W).
Age\>=20
You may not be if
History of hypersensitivity to empagliflozin
Breast-feeding, pregnant, possibly pregnant, or plan to become pregnant
Treated with insulin or SU
With renal dysfunction (eGFR\<45mL/min/1.73m2)
With liver dysfunction (AST or ALT is 3 times higher than reference value)
Hypotension (systolic blood pressure \< 90 mmHg)
With pituitary gland dysfunction or adrenal gland dysfunction
Heart failure patients whose NYHA class is IV
Deemed ineligible for the study due to another reason by investigator
History of diabetic ketoacidosis or diabetic come within 3 months before enrollment
History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment
Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment
Patients received SGLT2 inhibitor within 8 weeks before enrollment
